title: Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis.
abstract: The objective of this study was to examine the safety and efficacy of mizoribine (MZR), an inhibitor of inosine monophosphate dehydrogenase, in patients with connective tissue diseases (CTDs) other than rheumatoid arthritis. We identified all patients who had ever been treated with MZR for CTDs at our institution during the period from January 2001 to May 2011. A retrospective review of medical records was performed to evaluate safety and efficacy of MZR. A total of 63 patients (13 induction and 50 maintenance therapy with MZR) were included. During 70.2 patient-years of follow-up, only one patient required discontinuation of MZR due to an adverse event. Doses of PSL were significantly decreased at last follow-up in both the induction (45.2 ± 15.6 vs. 8.4 ± 5.7 mg/day, p < 0.01) and the maintenance group (12.4 ± 7.6 vs. 9.3 ± 6.4 mg/day, p < 0.01). MZR appears to be a safe and well-tolerated steroid-sparing agent in patients with CTDs.
authors.affiliation: Division of Allergy and Rheumatology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan, rrokutandah1@gmail.com.
authors.forename: Ryo
authors.initials: R
authors.lastname: Rokutanda
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Kishimoto
authors.forename: Sachiko
authors.initials: S
authors.lastname: Ohde
authors.forename: Hisanori
authors.initials: H
authors.lastname: Shimizu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nomura
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Suyama
authors.forename: Yuri
authors.initials: Y
authors.lastname: Ohara
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Masato
authors.initials: M
authors.lastname: Okada
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003240:Connective Tissue Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D007168:IMP Dehydrogenase